KALA BIO
KALA
105 hedge funds and large institutions have $283M invested in KALA BIO in 2020 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 26 increasing their positions, 28 reducing their positions, and 30 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less ownership
Funds ownership: 0.03% → 0.03% (-0%)
7% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 28
7% less funds holding
Funds holding: 113 → 105 (-8)
23% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 30
37% less capital invested
Capital invested by funds: $452M → $283M (-$168M)
67% less call options, than puts
Call options by funds: $1.09M | Put options by funds: $3.36M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$4.16M |
| 2 |
CC
Caxton Corporation
Princeton,
New Jersey
|
+$1.4M |
| 3 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
+$1.22M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$1.1M |
| 5 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$1.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$11.1M |
| 2 |
BBVA
Banco Bilbao Vizcaya Argentaria
Madrid,
Spain
|
-$8.39M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$5.33M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$3.95M |
| 5 |
Citigroup
New York
|
-$3.91M |
KALA Hedge Fund Activity: Q3 2020 in Review
105 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in KALA BIO (KALA) for Q3 2020, worth a combined $283M — down 37% from $452M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of KALA and 23 opened new positions — a net loss of 7 holders — while 28 trimmed existing stakes and 26 added.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $4.16M. The largest seller was Fidelity Investments, cutting an estimated $11.1M.
- 105 institutional investors held KALA BIO (KALA) as of Q3 2020, down from 113 in Q2 2020.
- Funds reported $283M of KALA BIO stock for Q3 2020, down 37% quarter-over-quarter.
- 23 funds opened new KALA BIO positions in Q3 2020 and 30 closed out, a net change of -7 holders.
- The largest KALA BIO buyer in Q3 2020 was Ikarian Capital, an estimated $4.16M added.
- The largest KALA BIO seller in Q3 2020 was Fidelity Investments, an estimated $11.1M sold.
Based on aggregated 13F filings for Q3 2020.